On July 29th, Gelunhui announced the performance forecast for the first half of 2024 for Sino Medical Sciences Technology Inc. (688108.SH). According to preliminary calculations by the company's finance department, the expected revenue for this reporting period is 0.214 billion yuan, an increase of 52.41 million yuan from the same period last year, a year-on-year increase of 32.49%.
During the reporting period, it is expected that the net income attributable to shareholders of the listed company will turn losses into profits compared with the same period last year, and the net income attributable to shareholders of the listed company will be 7.66 million yuan, an increase of 37.27 million yuan from the same period last year, a year-on-year increase of 125.88%. During the reporting period, it is expected that the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses will be -12.59 million yuan, an increase of 22.39 million yuan from the same period last year, a year-on-year increase of 64.00%.
